Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom.
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 4, p. 469, doi. 10.1007/s41030-024-00279-7
- By:
- Publication type:
- Article
Works matching IS 23641746 AND DT 2024 AND VI 10 AND IP 4
Results: 8
1
2
Do Antidepressants Worsen COPD Outcomes in Depressed Patients with COPD?
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 4, p. 411, doi. 10.1007/s41030-024-00277-9
- By:
- Publication type:
- Article
3
Survival Outcomes in US Medicare Patients with Non-Cystic Fibrosis Bronchiectasis by Rate of Baseline Exacerbations.
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 4, p. 439, doi. 10.1007/s41030-024-00275-x
- By:
- Publication type:
- Article
4
Comparison of Reporting Quality in National Cystic Fibrosis Patient Registries: Implications for Identifying Use of Novel CFTR Modulators.
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 4, p. 427, doi. 10.1007/s41030-024-00274-y
- By:
- Publication type:
- Article
5
Efficacy of High Flow Nasal Cannula in the Treatment of Patients with COVID-19 with Acute Respiratory Distress Syndrome: Results of Single Centre Study in Vietnam.
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 4, p. 451, doi. 10.1007/s41030-024-00272-0
- By:
- Publication type:
- Article
6
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 4, p. 377, doi. 10.1007/s41030-024-00271-1
- By:
- Publication type:
- Article
7
Is 'Cardiopulmonary' the New 'Cardiometabolic'? Making a Case for Systems Change in COPD.
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 4, p. 363, doi. 10.1007/s41030-024-00270-2
- By:
- Publication type:
- Article
8
A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis.
- Published in:
- Pulmonary Therapy, 2024, v. 10, n. 4, p. 483, doi. 10.1007/s41030-024-00269-9
- By:
- Publication type:
- Article